ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SAR Sareum Holdings Plc

24.25
-1.00 (-3.96%)
Last Updated: 15:55:35
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00BMC3RJ87 ORD GBP 0.0125
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -3.96% 24.25 24.00 24.50 25.25 24.25 25.25 486,000 15:55:35
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -3.19M -0.0469 -5.22 16.68M
Sareum Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 25.25p. Over the last year, Sareum shares have traded in a share price range of 10.20p to 147.50p.

Sareum currently has 68,069,416 shares in issue. The market capitalisation of Sareum is £16.68 million. Sareum has a price to earnings ratio (PE ratio) of -5.22.

Sareum Share Discussion Threads

Showing 17051 to 17063 of 17400 messages
Chat Pages: Latest  684  683  682  681  680  679  678  677  676  675  674  673  Older
DateSubjectAuthorDiscuss
20/4/2024
21:16
Advfn is not a public company..it's a private company.. it's data comes under the data protection act...

FOI only applies to government bodies and the like..

No wonder you are so stupid...

You don't even know basic stuff you fool!

wolfofwallstreets
20/4/2024
21:13
Wolfie boy fya

Which organisations are subject to FOI?
Organisations you can ask for information
government departments, devolved administrations, other public bodies and committees.
local councils.
schools, colleges and universities.
the NHS - including hospitals, GPs, dentists, pharmacists and opticians.
publicly owned companies.
publicly funded museums, galleries and theatres

And yes ADVFN is a publicly owned company...sleep well...ps you are still open to discuss my postvre 2014 and the interleukins

criticalthinker1
20/4/2024
21:13
Critical is that a copy and paste from 2014, don't take this the wrong way but if you're struggling and you're posts do come across as confusing and concerning there are people you can talk to that are available 24/7
iamhappy1
20/4/2024
21:06
OK! You wrote off 737 but let's skip that point albeit being in development beyond reportable parameters due to geographical loopholes with the contract.
So let's discuss the period of time drugs take to get through their progression and their novel ipr.
I draw your attention to this from 10 years ago and beg your esteemed knowledgeable response to genuinely respond that the progress despite its incursions has done nothing but progress. Be careful what you say as anything overly exemplary if offering financial advise is a two way street when being derogatory.

Psoriasis is a chronic autoimmune disease affecting the skin and characterized by aberrant keratinocyte proliferation and function. Immune cells infiltrate the skin and release proinflammatory cytokines that play important roles in psoriasis. The Th17 network, including IL-23 and IL-22, has recently emerged as a critical component in the pathogenesis of psoriasis. IL-22 and IL-23 signaling is dependent on the JAK family of protein tyrosine kinases, making JAK inhibition an appealing strategy for the treatment of psoriasis. In this study, we report the activity of SAR-20347, a small molecule inhibitor with specificity for JAK1 and tyrosine kinase 2 (TYK2) over other JAK family members. In cellular assays, SAR-20347 dose dependently (1 nM-10 μM) inhibited JAK1- and/or TYK2-dependent signaling from the IL-12/IL-23, IL-22, and IFN-α receptors. In vivo, TYK2 mutant mice or treatment of wild-type mice with SAR-20347 significantly reduced IL-12-induced IFN-γ production and IL-22-dependent serum amyloid A to similar extents, indicating that, in these models, SAR-20347 is probably acting through inhibition of TYK2. In an imiquimod-induced psoriasis model, the administration of SAR-20347 led to a striking decrease in disease pathology, including reduced activation of keratinocytes and proinflammatory cytokine levels compared with both TYK2 mutant mice and wild-type controls. Taken together, these data indicate that targeting both JAK1- and TYK2-mediated cytokine signaling is more effective than TYK2 inhibition alone in reducing psoriasis pathogenesis.

You have probably and hopefully worked out I'm setting you up for a fall and a FOI request into your posts that might be deemed a direct example of disparity to the hopeful success of a small bio with direct links to CRUK.

That's actually a criminal offence.

criticalthinker1
20/4/2024
20:52
Criticalstinker.

You don't have anything worth saying..

It's all..Emma walmsmey this...thoth said that.. who cares?

The market cap is now struggling on life support at 20 million thanks to donations from the happy clsppy brigade..

I don't care about sareum..it's compounds.. thoth..the month of the rerate or takeovers that you dream may happen..

Here are some facts..

Nothing achieved in 20 years...the BOD are rinsing the company hard with no success... bad RF deal destroys shareholder value.. desperate share placements to pay salaries...no certainty 1801 will do well..737 in limbo..no takeover... no licence..share consolidation which didn't work..no institutional interest...peel hunt involvement which hasn't worked...no rerate..no yacht party...the wombles were right..

Did I miss anything love?!

Do you need to change your pants as I'm sure your meds give you bowel problems..

wolfofwallstreets
20/4/2024
20:38
So 'iamhappy' and wolfie so knowledgeable about Sareum you are prepared to converse tonight? And maybe discuss my USDOD point?
Is that OK?
Or are you going to deflect and not discuss interleukins?
Because its rather a pertinent point if you want to back up your dismissive commentsxre Sareum.
You up for that?
Got your big boy pants on?

criticalthinker1
20/4/2024
19:58
USDOD that golden under funded nugget that's about exciting as an AUS CRO 😂 zero importance and zero relevance
iamhappy1
20/4/2024
19:42
Despite the naysayers it's worth thinking out of the box.

Some will see the concerns re autoimmune issues that are noteably increasing and cancer........................

This from Sareums website

Sareum is a clinical-stage small molecule company actively involved in developing next-generation kinase inhibitors to treat autoimmune diseases and cancer.

We recognise the crucial role of the TYK/JAK kinase cell signalling family in maintaining a healthy immune system, and our pipeline is primarily focused on this area of scientific and commercial interest.

I think it is noteable re a chat I had with Thoth and possible military interest re this new and interesting area that the big pharmas are wanting a chair at the table.

The military bit is just a thing I'm putting out there for critical thinkers but you can research further if you have the time...Sareum has links with its ipr to the USDOD.

I'm getting the early doors vibe similar to Novacyt and I suspect that there are others under the threshold value to be named are aware of this too.

Albeit by a grey way of entry. The grey individuals don't get in by the back door..they use the back door to the back door to remain incognito.

And hats off to those of us who bailed the company out.

But We still need to consider if (when various licences are granted as purported due to multiple applications but psoriasis is the holy grail of initial drugs going into other applications...hence 1802) the right individuals are in the right positions re 'ongoing discussions'.

All best. Love the science. Need some returns from the boards questionable prior agreement with RF...but selling your soul comes at a cost...

criticalthinker1
20/4/2024
19:34
Norma stitz mk3 astra' same era as sareums kinase inhibitor library now there's a classic that under performs no amount of go faster stripes will change that not even a buy 1 get 1 free
iamhappy1
20/4/2024
19:10
No mass sell off 😂 follow the money riverfort are dumping quick smart or follow the science and good luck finding any meaningful data
iamhappy1
20/4/2024
17:49
Thanks pete
horridhenry
20/4/2024
16:28
It's you're Henry.
peaceandlove
20/4/2024
14:20
Now Norma Champions league, just hoping for Premier league next season, tide will turn tomorrow against Forest, well I fe.kin hope it does.The FA and wealth manager kills me whenever I think of it.See it was talking to itself at midnight on here again yesterday. One very sad life.
silvergreyhead1
Chat Pages: Latest  684  683  682  681  680  679  678  677  676  675  674  673  Older

Your Recent History

Delayed Upgrade Clock